Literature DB >> 6367679

Thromboembolism in patients with the 'lupus'-type circulating anticoagulant.

M Elias, A Eldor.   

Abstract

Thirty-five patients with the lupus anticoagulant (LA) were followed up between 1975 and 1982. The most prevalent clinical manifestation occurring in these patients was thrombosis. Nineteen patients (54.3%) had a single or recurrent thrombotic episode. Fifteen patients (42.8%) had venous thrombosis, and arterial thrombosis manifested by stroke or transient ischemic attacks occurred in six patients. Bleeding occurred in only five patients, four of whom had severe thrombocytopenia, while no excessive bleeding was noted during 18 operative procedures. Various therapeutic regimens, including corticosteriods, nonsteroidal anti-inflammatory drugs, cytotoxic or immunosuppressive agents, had no effect on the presence of the LA in these patients. Anticoagulants were successful in the treatment and prevention of thrombotic episodes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6367679

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  41 in total

Review 1.  Hepatic manifestations of autoimmune rheumatic diseases.

Authors:  S Abraham; S Begum; D Isenberg
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

2.  Phlegmasia cerulea dolens associated with the lupus anticoagulant.

Authors:  B A Baethge; D K Payne
Journal:  West J Med       Date:  1991-02

Review 3.  The antiphospholipid syndrome: a syndrome in evolution.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

4.  Superior mesenteric artery thrombosis associated with antiphospholipid syndrome.

Authors:  M E Hamilton
Journal:  West J Med       Date:  1991-08

5.  Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome.

Authors:  P A Ostuni; P Lazzarin; V Pengo; A Ruffatti; F Schiavon; P Gambari
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

Review 6.  Antiphospholipids--a "guilty ghost" syndrome.

Authors:  M Vayssairat; N Abuaf; J P Gaitz; N Baudot
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 7.  Treatment of the antiphospholipid syndrome.

Authors:  J C Piette; M Karmochkine; T Papo; L T Du; C Francès; B Wechsler
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

8.  Anti-Klebsiella K30 phospholipid antibodies in systemic lupus erythematosus: antigen cross-reactions and idiotypic sharing with antibodies to DNA and Klebsiella K30 polysaccharide.

Authors:  G D Harkiss; F M Hendrie; D Thompson
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

9.  The anti-phospholipid antibody syndrome in a 77 year old man with digital gangrene.

Authors:  S W Roche; D C Niriella; A O'Mahoney; A C Cayley
Journal:  Postgrad Med J       Date:  1989-11       Impact factor: 2.401

10.  Fetal loss treatment in patients with antiphospholipid antibodies.

Authors:  J Ordi; J Barquinero; M Vilardell; R Jordana; C Tolosa; A Selva; E Genover
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.